Neurosciences, psychiatry Nervous System Diseases Dementia
Conditions
Interventions
Randomised to receive:
1. Risperidone 0.5-1.0 mg
2. Donepezil 5-10mg
3. Placebo
For 12 weeks.
Sponsors
King's College London (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Probable or possible Alzheimer's disease (AD) 2. Clinically significant agitation 3. Age >39 years 4. Resident in care facility or community resident with carer 5. Not receiving treatment with neuroleptics or chlornesterase inhibitors 6. Carer with capacity to consent.
Exclusion criteria
Exclusion criteria: 1. Known sensitivity to donepezil or resperidone 2. Severe, unstable or uncontrolled medical conditions apparent from history, physical examination or investigations 3. Current evidence of delirium 4. Patient meets criteria for Probable Dementia with Lewy Bodies (McKeith et al, 1996) 5. Low probability of treatment compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A reduction in score on the Cohen Mansfield Agitation Inventory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed